JPMorgan Chase & Co. Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $170.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price lifted by JPMorgan Chase & Co. from $167.00 to $170.00 in a research note published on Friday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

Several other analysts have also recently commented on ASND. Cantor Fitzgerald reiterated an overweight rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, April 18th. Wedbush upped their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an outperform rating in a report on Thursday, February 8th. Citigroup raised their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a report on Thursday, February 8th. Wells Fargo & Company upped their price target on Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an overweight rating in a research note on Friday, March 15th. Finally, Morgan Stanley reissued an equal weight rating and set a $116.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, April 22nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $173.88.

Ascendis Pharma A/S Stock Down 2.8 %

ASND stock opened at $137.20 on Friday. The business has a fifty day moving average of $146.67 and a 200-day moving average of $128.07. The company has a market cap of $7.99 billion, a P/E ratio of -14.28 and a beta of 0.54. Ascendis Pharma A/S has a twelve month low of $83.75 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The company had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -4.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new stake in Ascendis Pharma A/S during the 1st quarter worth approximately $992,000. FORA Capital LLC acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth $703,000. Tobam lifted its position in Ascendis Pharma A/S by 41.1% in the 1st quarter. Tobam now owns 2,163 shares of the biotechnology company’s stock valued at $327,000 after acquiring an additional 630 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Ascendis Pharma A/S by 4,231.4% in the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after purchasing an additional 73,796 shares during the period. Finally, Matisse Capital increased its holdings in Ascendis Pharma A/S by 2.6% during the 1st quarter. Matisse Capital now owns 35,540 shares of the biotechnology company’s stock worth $5,373,000 after purchasing an additional 905 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.